Browse studies
Find your next paid study
14 recruiting studies matching your filters
Phase 2
Phase II Randomized Study of Ruxolitinib vs Prednisone as First-Line Therapy for Chronic Graft vs Host Disease Needing Systemic Therapy
Allogeneic transplant is potentially curative for hematological malignancies but its use is limited by the development of GVHD. Ruxolitinib now has FDA approva…
Chronic Graft-versus-host Disease (cGVHD)
Estimated
~$10 – $6,250
H. Lee Moffitt Cancer Center and Research InstituteNCT06660355
Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) With Low-Dose Post-Transplant Cyclophosphamide for Prophylaxis of Graft-versus-Host Disease in Hematological Malignancies
This Phase 2, single-arm, open-label study aims to evaluate the safety and efficacy of low-dose (25 mg/kg) post-transplant cyclophosphamide (PTCy) for prophyla…
Graft-versus-Host Disease (GVHD)Hematologic MalignanciesAllogeneic Stem Cell Transplantation
Estimated
~$10 – $6,250
Milton S. Hershey Medical CenterNCT06926595